Safety of topiramate: Adverse events and relationships to dosing

Epilepsia

Volumn 37, Issue SUPPL. 2, 1996, Pages

  Shorvon, Simon D ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Adverse events; Anticonvulsants; Epilepsy; Seizures; Therapy; Topiramate

Indexed keywords

TOPIRAMATE;

ANTICONVULSANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIPLOPIA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; EPILEPSY; FATIGUE; HUMAN; NEPHROLITHIASIS; NYSTAGMUS; PRIORITY JOURNAL; VERTIGO;

EID: 0029954487     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb06029.x     Document Type: Conference Paper

References (22)

1. Maryanoff BE, Nortez SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl sulfamates in 2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfate and related compounds. J Med Chem 1987;30:880-7.
2. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-64.
3. Pledger G, Reife R, Lim P, Karim R. Overview of topiramate efficacy from adjunctive therapy trials. Epilepsia 1995;36(suppl 3):150.
4. Data on file. R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, U.S.A.
5. Mattson RH, Cramer JA, Collins J, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidine in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
6. Brodie MJ. Established anticonvulsants and treatments of refractory epilepsy. Lancet 1990;336:350-54.
7. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
8. Sander JWAS, Trevisol-Bettencourt PC, Hart YM, Patsalos PN, Shorvon SD. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990;7:226-9.
9. Matsuo F, Bergen O, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
10. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:111.
11. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled study. Neurology 1993;43:2292-8.
12. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34 (suppl 2):123.
13. Brown SD, Wolf HH, Swinyard ED, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):122-3.
14. White HS, Brown SD, Skeen GA, et al. The anticonvulsant topiramate displays a unique ability to potentiate GABAevoked chloride currents. Epilepsia 1995;36(suppl 3):39.
15. Wasserstein A, Reife R, Rak I. Mechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constituents. Epilepsia 1995;36(suppl 3):153.
16. Trimble MR. The psychosis of epilepsy. New York: Raven Press, 1991.
17. Mendez MF, Grau R, Doss RC, Taylor JL. Schizophrenia in epilepsy: seizure and psychosis variables. Neurology 1993; 43:1073-7.
18. Spielberg S, Gordon G, Blake D, Goldstein D, Herlong A. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-8.
19. Schmidt D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982.
20. Zafrani ES, Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982;2:6487.
21. Treiman DM. Efficacy and safety of antiepileptic drugs: a review of controlled trials. Epilepsia 1987;28(suppl 3):S1-S8.
22. Heydorn WE. Felbamate - rise and fall of a novel antiepilepsy compound. Expert Opin Invest Drugs 1994;3:1205-8.